When gastrointestinal tract starts losing its wellbeing, you know what comes next
While our study provides valuable insights into the mechanisms by which C3G enhances GLP-1 secretion and insulin release, several limitations should be acknowledged
Adam Felman Author Carmen Chai Author Carmen Chai is a Canadian journalist and award-winning health reporter
However, in clinical trials promising pre-clinical studies have not been translated into positive outcomes 12,13
Its another tool in the toolbox. While weight loss drugs have been around for years, the new batch of GLP-1 receptor agonists, which include Wegovy (semaglutide) and Zepbound (tirzepatide), are making headlines every day
Studies of semaglutide and hypothyroidism subgroups in weight-loss trials have shown comparable efficacy and safety to non-hypothyroid participants, with no pharmacodynamic antagonism documented